What do systematic reviews say?

Outcomes* · people with open‐angle glaucoma

Progression of visual field loss (worsening of one or more stages, accordingto the Glaucoma Staging System‐2) (at 12 months) · people with open‐angle glaucoma

Decrease in visual acuity · people with open‐angle glaucoma

Mean intraocular pressure · people with open‐angle glaucoma

Vertical cup‐disc ratio: the proportion of participants with asymmetrical vertical cup‐disc ratio greater than 0.3 at 4 years' · people with open‐angle glaucoma

Adverse effects: ocular allergy to the study medication requiring discontinuation up to 4 years' · people with open‐angle glaucoma

Quality of life measures · people with open‐angle glaucoma

Cost / economic data · people with open‐angle glaucoma

Death (fetal, neonatal, or later (up to 2 years' corrected age))** · women at risk of preterm birth (< 34 weeks' gestation)

Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)

Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)

Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)

Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)

Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)

Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)

Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)

Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)

Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)

Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)

Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)